Novartis AG ADR (NVS)vsTG Therapeutics Inc (TGTX)
NVS
Novartis AG ADR
$140.98
+0.21%
HEALTHCARE · Cap: $260.70B
TGTX
TG Therapeutics Inc
$58.11
+1.66%
HEALTHCARE · Cap: $8.75B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6991% more annual revenue ($56.69B vs $799.54M). TGTX leads profitability with a 55.2% profit margin vs 22.5%. TGTX appears more attractively valued with a PEG of 1.61. TGTX earns a higher WallStSmart Score of 56/100 (C).
NVS
Buy51
out of 100
Grade: C-
TGTX
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-50.3%
Fair Value
$93.40
Current Price
$140.98
$47.58 premium
Intrinsic value data unavailable for TGTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Every $100 of equity generates 79 in profit
Keeps 55 of every $100 in revenue as profit
Revenue surging 70.3% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Expensive relative to growth rate
Trading at 14.1x book value
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : TGTX
The strongest argument for TGTX centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 55.2% and operating margin at 9.0%. Revenue growth of 70.3% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : TGTX
The primary concerns for TGTX are PEG Ratio, Price/Book, Debt/Equity.
Key Dynamics to Monitor
NVS profiles as a value stock while TGTX is a growth play — different risk/reward profiles.
TGTX carries more volatility with a beta of 1.66 — expect wider price swings.
TGTX is growing revenue faster at 70.3% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
TGTX scores higher overall (56/100 vs 51/100), backed by strong 55.2% margins and 70.3% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →TG Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?